RSV Antibody Treatment Effective For Babies

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 6, 2025.

By Dennis Thompson HealthDay Reporter

TUESDAY, May 6, 2025 -- Newborns can be effectively protected against respiratory syncytial virus (RSV) infection through the use of nirsevimab, a monoclonal antibody treatment, researchers report.

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in The Lancet Child & Adolescent Health.

The antibody treatment also reduced the risk of intensive care admissions by 81% and instances of lower respiratory tract infections by 75% in children younger than 1 year old, results show.

Nirsevimab also was more effective in preventing RSV-related hospitalizations in infants older than 3 months (81%) compared to those 3 months or younger (76%), researchers report.

“Our findings indicate that the benefits of nirsevimab observed in clinical trials are also evident in real-world settings, effectively reducing the burden of RSV disease in infants and, consequently, health-care use,” concluded the team led by senior researcher Seyed Moghadas, a professor of computational epidemiology and vaccine science with York University in Ontario, Canada.

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two methods. An expectant mother can pass on protection by getting an RSV vaccine while pregnant, or a newborn can be given antibody treatment to protect them against RSV.

To check the effectiveness of nirsevimab, researchers combined data from 27 studies conducted during the 2023-2024 RSV season across five countries — France, Italy Luxembourg, Spain and the United States.

Although the protection from the antibody treatment was high, researchers found that its effectiveness did vary by country.

The U.S. had higher effectiveness, with 93% of treated infants avoiding hospitalization, compared with 83% in Spain and 76% in France.

That might be because more babies who got the antibody treatment were at high risk of severe disease in the U.S., researchers said. The U.S. prioritized nirsevimab treatment for high-risk infants during the season under study, due to a limited supply of the antibody treatment.

“Our findings underscore the importance of infant immunization programs in alleviating the health and economic burden of RSV disease in the high-risk period following birth,” researchers concluded.

Sources

  • The Lancet, news release, May 1, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-05-07 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords